EN DE
Watch Novartis AG for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Novartis AG (NVS) fair value: what the stock is really worth

As of Nov 20, 2026: fair value (intrinsic value) of Novartis AG stock $145.45, price $150.47, that is 3.3% below the price, quality 86 out of 100. Rating: fairly valued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ADR · Home Switzerland · ISIN US66987V1098

This is a secondary listing. View primary listing Novartis AG (NOVN.SW) →

NA Novartis AG logo Broad data Nov 21, 2026

Novartis AG

NVS · US

Strong company and rising price, but the stock is already about fairly priced: meets 2 of 3 rules.

Follow free in the weekly email
Quality 86/100 
Rising price (uptrend) 
Highly profitable · 22.5% net margin (TTM) 
Generates free cash flow 
3.1% dividend yield · Sustainable
Ranks above peers (10/14) 
Wide moat 88/100
Broad data 
30% return on equity. 
Fair value $145.45 · Fairly valued 
Moderate debt 
Recent news mixed 
Weak Growth (revenue 5y +1.9 %/yr in USD) 
US receipt (ADR)
Watch Novartis AG for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$164.98 $64.46 Fair Value $145.45 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 21, 2026.

How to read this chart

60‑month range $64.46 – $164.98 · fair‑value band $105.73 – $185.17 · the $150.47 price screens above the $145.45 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 21, 2026.

Follow Novartis in your weekly email

Every Wednesday you see whether Novartis is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.

Show moreShow less

The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta.

The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology.

It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Stock analysis

Novartis AG (NVS) currently trades at $150.47, while our model-based Fair Value estimate is $145.45, so the stock looks roughly fairly valued today (gap 3.4%).

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $168.05 per share, and 10 of the 23 models we run sit above the $150.47 price.

Bear case: the Economic Profit group reads lowest at $84.49, and 13 of the 23 models stay below the price. Data coverage for this calculation is high.

Scenario range: $105.73 (bear) to $185.17 (bull), the price of $150.47 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 86/100 (high quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Novartis AG reported revenue of $54.8B in FY2025 versus $44.0B in FY2021, a compound +5.7%/yr. Reported net income was $14.1B in FY2025, compounding −12.5%/yr from FY2021.

Key figures

Market cap $288B Mega · P/E ratio 22.7 · P/S ratio 5.08 · EPS (TTM) $6.62 · Dividend yield 3.1% · Net margin 22.5% · Return on equity 30.4% · Return on assets (EBIT) 10.6% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 88 out of 100 (medium confidence).

What moves the price

The share trades about 9% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −3% fair-value upside, at −3%, NVS screens cheaper than that median.

Fair Value models

Bear $105.73 Fair Value $145.45 Bull $185.17
Price $150.47 · Downside -3.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 11 months old). Earnings retained since then ($1.75 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $120.78 $194.48 $322.09 78
Growth DCF $126.59 $197.34 $315.61 77
Owner Earnings $100.64 $162.88 $270.65 75
All 23 models by family
DCF Models
FCF DCF $120.78 $194.48 $322.09 78
Owner Earnings $100.64 $162.88 $270.65 75
5Y Revenue Exit $72.79 $107.89 $150.41 73
5Y EBITDA Exit $109.45 $173.18 $244.21 75
5Y P/E Exit $108.28 $171.10 $233.62 71
10Y Revenue Exit $85.40 $121.36 $164.74 67
10Y EBITDA Exit $112.09 $168.80 $238.28 68
10Y P/E Exit $111.31 $167.30 $229.98 64
Earnings-Based
Graham-Dodd $52.16 $122.70 $157.93 65
PEG = 1.0 $52.06 $74.38 $96.68 57
EPV $80.97 $99.04 $115.77 74
Dividend Discount
Gordon GGM $82.09 $159.20 $285.03 65
DDM Multi-Stage $82.09 $129.89 $192.09 66
Multiples
P/E Multiple $126.56 $168.75 $210.92 63
P/S Multiple $78.52 $104.69 $130.86 58
EV/EBIT $105.40 $145.01 $184.60 66
EV/EBITDA $115.10 $157.94 $200.77 67
EV/Revenue $49.42 $76.34 $103.25 53
Growth DCF
Growth DCF $126.59 $197.34 $315.61 77
Rev-Margin DCF $72.79 $109.54 $149.46 73
Economic Profit
Residual Income $48.39 $58.15 $100.00 74
ROIC Compounder $85.41 $110.84 $139.87 72
Growth Earnings
Growth-Adj P/E $95.52 $136.44 $177.38 67

Models of NOVN.SW, converted to this listing with the same factor as the fair value.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 86/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 75
How much profit the company makes from its sales and capital
Quality Growth 55
Are margins and returns getting better?
Cashflow 88
Do the profits arrive as real cash?
Financial strength 70
Debt, balance sheet and risk of trouble
Investment 98
Does it invest with discipline instead of growing at any price?
Low Volatility 91
How calm the share price moves, does not count
Price momentum 55
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 72
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 40/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+6.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.9%
Start year 2020 (pandemic). Over 10 years: +0.8% a year
Revenue growth 27 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.3%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+17.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year+14.4%
Dividend (yield on the price)3.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.7.3% vs 5.7%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.20% → 31%
Pace: the 5-year rate starts in 2020 (pandemic)

Growth Forecast

Little optimism in the price
The price assumes about as much growth as the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+1.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+5.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −0.9% a year for the price and +3.1% for the forecasts.
Forecast 2026 (sales)+5.2%
Forecast 2027 (sales)+6.4%
Projected 2028 (sales)+5.9%
Projected 2029 (sales)+5.3%
Projected 2030 (sales)+4.8%

Watch NVS, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.

Compare Novartis AG with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 71 stocks

Beats the industry median on 10/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 84 · Top 25%
Fair Value upside −3.3% · Above median
Profitability
Return on equity (12 months) 30.4% · Top 25%
Return on assets 12.2% · Top 25%
Net margin (12 months) 22.5% · Top 25%
Operating margin (12 months) 34.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 0.8% · Bottom 25%
Dividend yield (12 months) 3.1% · Above median
Balance sheet
Debt / equity 0.90× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper

P/E (12 months) 22.7× · Cheaper than median
P/B 6.24× · book value is mostly intangible assets ⓘGoodwill and other intangible assets (such as prices paid for past acquisitions, brands, licences or film and series rights) are larger than the equity. So we do not rank this P/B against the peer group.
P/S (12 months) 5.08× · Pricier than median
Price / free cash flow (fiscal year) 16.3× · Cheaper than median
EV/EBITDA 13.2× · Cheaper than median
PEG 3.34× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)29 · sector 29
FUTURE (revenue growth)4 · sector 36
PAST (return on equity)100 · sector 41
HEALTH (low debt)55 · sector 92
DIVIDEND (yield)62 · sector 37

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Sanofi SNY $46.52 $68.92 +48% vs NVS
Bristol-Myers Squibb Company BMY $58.80 $75.91 +29% vs NVS
Amgen Inc AMGN $435.64 $479.20 +10% vs NVS
Gilead Sciences, Inc GILD $166.43 $183.07 +10% vs NVS
Merck & Co MRK $133.72 $129.26 −3% vs NVS
Pfizer Inc PFE $27.40 $24.87 −9% vs NVS
AbbVie Inc ABBV $286.20 $259.62 −9% vs NVS
Roche Holding RO CHF 402.60 CHF 326.56 −19% vs NVS
Johnson & Johnson, JNJ $270.47 $169.03 −38% vs NVS
Eli Lilly and Company LLY $1,347.11 $749.92 −44% vs NVS

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Novartis AG: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Novartis AG Fair Value". https://www.fairvalue-calculator.com/stock/NVS.US

Frequently asked questions

Is Novartis AG (NVS) overvalued or undervalued?
As of Nov 21, 2026, our model estimates a fair value of $145.45 versus a price of $150.47, about 3% lower (fairly valued).
What is the fair value of NVS?
Our model-based fair value for Novartis AG is $145.45 (as of Nov 21, 2026), built from audited fundamentals. The current price: $150.47.
What is the quality score of NVS?
Novartis AG has a Quality Score of 86/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Novartis AG (NVS)?
We do not set a price target; the yardstick is the fair value of $145.45 (as of Nov 21, 2026) from 23 valuation models. Cautious scenario $105.73, optimistic scenario $185.17. It is a calculation from audited fundamentals, not an analyst target.
What is the Novartis AG stock forecast for 2026?
Our models put fair value at $145.45, about 3% lower versus a price of $150.47 (fairly valued). Cautious scenario $105.73, optimistic scenario $185.17. The calculation is refreshed regularly with new filings.
What is the revenue of Novartis AG (NVS)?
Novartis AG reported trailing-twelve-month revenue of about $56.7B (latest available figure, as of Nov 21, 2026).
Does Novartis AG pay a dividend?
Novartis AG currently shows a dividend yield of 3.10% relative to its recent price (as of Nov 21, 2026).
How much is the dividend of Novartis AG (NVS) and when is the ex-dividend date?
Novartis AG pays a dividend of $4.67 per share a year, a dividend yield of 3.1%. The last ex-dividend date was Mar 11, 2026. A dividend has been paid every year since at least 1997. The payout ratio is 70.5% of earnings. Free cash flow covers the dividend 1.99 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into Novartis AG (NVS)?
For today's price to be fair in a discounted-cash-flow model, Novartis AG would have to grow free cash flow by 1.5 % per year for five years (discount rate 7.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 1.9 % per year. As of Nov 21, 2026.
What discount rate (WACC) does the fair value of NVS use?
Our models discount Novartis AG at 7.6 %: a base by market capitalisation (mega), damped by beta 0.47, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Novartis AG that is +1.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (7.6 %) and the same formula as our fair value.
How much growth has Novartis AG (NVS) delivered so far?
Over the past 5 years revenue at Novartis AG grew 1.9 % a year. The price currently implies free-cash-flow growth of +1.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Novartis AG (NVS) growing?
The median revenue growth in the sector is +7.3 % a year. That is the yardstick for the growth priced into Novartis AG (+1.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Novartis AG (NVS)?
The free-cash-flow yield on the price is 6.14 %: that much free cash flow Novartis AG produces per unit of market value. When it exceeds the discount rate of our models (7.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Novartis AG (NVS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Novartis AG it is $145.45 per share (as of Nov 21, 2026), against a price of $150.47. It is the blended result of 23 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Novartis AG stock overvalued or undervalued in 2026?
As of Nov 21, 2026, NVS trades above its calculated fair value: price $150.47, fair value $145.45, a gap of about −3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NVS?
No. The price is what the market pays today ($150.47); the fair value is what the company's own numbers justify ($145.45). For Novartis AG the two are $5.02 per share apart. That gap is exactly why we show both numbers side by side.
How much is Novartis AG worth?
The market values Novartis AG at about $288B (market capitalisation, as of Nov 21, 2026). Per share that is $150.47; our models calculate a fair value of $145.45 per share.
What do the bullish and bearish scenarios say about NVS?
Our models span a range for Novartis AG: cautious scenario $105.73, base $145.45, optimistic $185.17 per share (as of Nov 21, 2026, price $150.47). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NVS?
Novartis AG trades at a price-to-earnings ratio of 22.7 (as of Nov 21, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $145.45 is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2019 to 2025), reported earnings, 4 of the years ex one-offs: 25.6. Other multiples: PEG 3.3, P/B 6.2, P/S 5.1, EV/EBITDA 13.2.
What is the PEG ratio of NVS?
The PEG ratio of Novartis AG is 3.34 (P/E divided by earnings growth, as of Nov 21, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Novartis AG (NVS)?
Balance-sheet figures for Novartis AG (as of Nov 21, 2026): return on equity 30.4%, debt of 0.90 per unit of equity (balance sheet 30 Jun 2026). They feed the Quality Score of 86/100, which uses the fiscal-year figures and measures business quality independently of the share price.
How far is NVS from its 52-week high?
Novartis AG trades at $150.47, about 9% below its 52-week high of $164.98 and 25% above the low of $120.69 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of $145.45 is for.
Which stocks are comparable to Novartis AG?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Novartis AG stock attractive at the current price?
The data as of Nov 21, 2026: price $150.47, calculated fair value $145.45 (−3%), Quality Score 86/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NVS calculated?
We run Novartis AG through 23 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $145.45 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 10.1% above its aggregate fair value. Novartis AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Novartis AG (NVS)?
The closing price on Nov 20, 2026 was $150.47. Our model-based fair value is $145.45, about 3% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Novartis AG right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the upper half of our model range, so the margin of safety is thin. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Novartis AG (NVS) come from?
Earnings per share at Novartis AG grew 3.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share +2.0 %, EBIT margin +4.3 %, tax rate −0.1 %, residual (interest, one-offs) −2.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Novartis AG

How large is the market capitalisation of Novartis AG (NVS)?
The market capitalisation of Novartis AG is $288B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Novartis AG (NVS)?
The price-to-sales ratio of Novartis AG is 5.08 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Novartis AG (NVS)?
Earnings per share at Novartis AG are $6.62 (price ÷ EPS = P/E 22.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Novartis AG (NVS)?
The dividend yield of Novartis AG is 3.1% (payout 70.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Novartis AG (NVS)?
The net margin of Novartis AG is 22.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Novartis AG (NVS)?
The return on equity (ROE) of Novartis AG is 30.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Novartis AG (NVS)?
On an EBIT basis the return on assets of Novartis AG is 10.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Novartis AG (NVS)?
The operating margin of Novartis AG is 34.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Novartis AG (NVS)?
Revenue at Novartis AG is growing 0.8% in the last quarter versus the same quarter a year earlier (3y avg +8.0%). How much revenue grew in the last quarter versus the same quarter a year earlier (YoY). The 3-year average next to it puts the single quarter in context.
How fast are earnings growing at Novartis AG (NVS)?
Earnings per share at Novartis AG are down 17.0% in the last quarter versus the same quarter a year earlier. How much earnings per share grew in the last quarter versus the same quarter a year earlier.
How much net debt does Novartis AG (NVS) carry?
The net debt of Novartis AG is $41.4B (balance sheet 30 Jun 2026, ≈ 2.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Novartis AG in the live analysis

One click puts Novartis AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.